Cancer vaccines show promise in pancreatic cancer clinical trials

Recent clinical trials have shown promising results in using cancer vaccines to treat pancreatic cancer. These immunotherapy approaches aim to train the immune system, specifically T cells, to identify and destroy cancer cells. Notable developments include the AMPLIFY-201 trial evaluating ELI-002 2P, autogene cevumeran developed by Memorial Sloan Kettering, and mKRAS-VAX from Johns Hopkins University School of Medicine.

Historically, standard immunotherapy such as immune checkpoint inhibition (ICI) has struggled to treat pancreatic cancer due to a heavily immunosuppressive tumor microenvironment. This environment includes a dense, fibrotic stroma that can make up over 80% of the tumor mass. Researchers are currently investigating how the morphology and function of cancer-associated fibroblasts within this stroma might serve as biomarkers to improve treatment strategies and decision-making.